Wealth Enhancement Advisory Services’s Ironwood Pharmaceuticals IRWD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$777K Sell
214,094
-5,351
-2% -$22.3K ﹤0.01% 2382
2026
Q2
$913K Sell
219,445
-7,243
-3% -$27.9K ﹤0.01% 2139
2026
Q1
$741K Buy
226,688
+71,165
+46% +$292K ﹤0.01% 2025
2025
Q4
$665K Buy
155,523
+1,135
+0.7% +$2.95K ﹤0.01% 2262
2025
Q3
$235K Buy
154,388
+28,928
+23% +$29.9K ﹤0.01% 2989
2025
Q2
$96.1K Buy
125,460
+101,574
+425% +$79.7K ﹤0.01% 3144
2025
Q1
$35.1K Buy
23,886
+10,651
+80% +$25.4K ﹤0.01% 2874
2024
Q4
$58.6K Buy
+13,235
New +$53.7K ﹤0.01% 2854
2024
Q3
– Sell
-13,608
Closed -$88.7K – 2863
2024
Q2
$88.7K Buy
+13,608
New +$96.3K ﹤0.01% 2417

Other funds holding IRWD

Wealth Enhancement Advisory Services's IRWD Position: Q3 2026 in Review

Wealth Enhancement Advisory Services reduced its Ironwood Pharmaceuticals (IRWD) stake by 2.4% in Q3 2026, selling an estimated $22.3K and leaving 214,094 shares worth $777K. The position accounts for ﹤0.01% of the portfolio, ranked #2382.

Wealth Enhancement Advisory Services first reported a position in IRWD in Q2 2024 and has held it in 9 quarters since. The position peaked at $913K in Q2 2026. 37 funds tracked by Wall St. Rank hold IRWD as of Q3 2026.

  • Wealth Enhancement Advisory Services held 214,094 shares of Ironwood Pharmaceuticals worth $777K as of Q3 2026.
  • Wealth Enhancement Advisory Services sold 5,351 Ironwood Pharmaceuticals shares in Q3 2026, an estimated $22.3K.
  • Ironwood Pharmaceuticals made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q3 2026, its #2382 holding.
  • Wealth Enhancement Advisory Services first reported a position in Ironwood Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
  • Wealth Enhancement Advisory Services's Ironwood Pharmaceuticals position peaked at $913K in Q2 2026.
  • 37 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q3 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q3 2026, filed 13 Oct 2026.